Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery
The exponential growth of nanotechnology has focused on therapeutic pursuits, notably for brain disorders. Nanocarriers have submicron particle sizes, typically around 500 nm. Over the past few years, interest in nanostructured lipid carriers as alternative pharmaceutical delivery systems has increased on both the scientific and commercial fronts. It belongs to a more recent incarnation of lipid nanoparticulate systems with a solid matrix and superior room temperature stability. More recently, they have also been used in gene therapy, cancer treatment, and brain targeting. In this review, the uses and significance of nanostructured lipid carriers (NLC) in combating brain diseases have been thoroughly covered, with examples from several recent research papers.
A summary of NLCs’ present patent status has been provided to highlight their promising potential. Related patents and research reports associated with this topic are gathered and availed. The paper thoroughly summarizes NLCs and their application in different routes of administration. Drug administration directly to the brain via nose through NLCs is mainly focused. Nose-to-brain delivery has more benefits compared to the other routes. NLCs provide significant advantages such as targeted delivery, less toxicity, higher drug loading capacity due to imperfect structure, etc. However, the particle size of NLCs for intranasal drug delivery should be < 200 nm. Also, NLC is combined with a medical device to achieve the add-on benefits for delivering drugs effectively.
According to the comprehensive review of literature and patents like CN110013471B, IN-MUM-2015-00667A, IN202021023420A, and AU2021104270A4, drug-loaded NLCs in nose-to-brain delivery show promising results. NLCs can increase bioavailability and reduce dosing frequency, indirectly reducing dose-related side effects. Intervening NLCs directly on the targeted site displays site specificity and many more benefits than conventional dosage forms. Thus, using NLCs in nose-to-brain drug delivery is invigorating.
Read more here
Shah, S., Patel, A.A., Prajapati, B.G. et al. Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery. J Nanopart Res 25, 150 (2023). https://doi.org/10.1007/s11051-023-05804-4
Watch our free webinar “Rx & OTC Product Line Extensions with Oral Lipid-Based Delivery Platforms” here:
